Skip to content
OpenCapital
Get started

Integra LifeSciences IART EV / EBITDA

EV / EBITDA at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
Stryker logo
StrykerSYK
22.1×-11.8×
Globus Medical logo
Globus MedicalGMED
13.8×-4.9×
AbbVie logo
AbbVieABBV
19.8×—
Medtronic logo
MedtronicMDT
13.9×-1.5×
STERIS logo
STERISSTE
14.7×-3.5×

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%—
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%—
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Calculated from Integra LifeSciences’s reported figures.

enterprise value/ebitda=19.7×

Based on the most recent quarter.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's EV / EBITDA?
Integra LifeSciences (IART) reported EV / EBITDA of 19.7× in Q1 2025.
How has Integra LifeSciences's EV / EBITDA changed year-over-year?
Integra LifeSciences's EV / EBITDA increased by 22.7% year-over-year, from 16.1× to 19.7×.
What is the long-term trend for Integra LifeSciences's EV / EBITDA?
Over 4 years (2020 to 2024), Integra LifeSciences's EV / EBITDA has grown at a -5.1% compound annual growth rate (CAGR), from 21.6× to 17.6×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.